Semaglutide drug class
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Drug Class: An Overview
Introduction to Semaglutide and GLP-1 Receptor Agonists
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA), a class of drugs used primarily for the treatment of type 2 diabetes. GLP-1RAs work by mimicking the incretin hormone GLP-1, which increases insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby improving glycemic control and promoting weight loss1 2 3.
Formulations and Administration
Semaglutide is unique among GLP-1RAs as it is available in both subcutaneous and oral formulations. The subcutaneous form is administered once weekly, while the oral form is taken daily. The oral formulation includes an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which facilitates the drug's absorption in the stomach2 8.
Efficacy in Glycemic Control and Weight Loss
Clinical trials have consistently demonstrated the efficacy of semaglutide in improving glycemic control and promoting weight loss. In the PIONEER 5 trial, oral semaglutide significantly reduced HbA1c levels and body weight in patients with type 2 diabetes and moderate renal impairment3. Similarly, the SUSTAIN 9 trial showed that adding semaglutide to SGLT-2 inhibitor therapy resulted in greater reductions in HbA1c and body weight compared to placebo4. The STEP 2 trial further confirmed the superior weight loss effects of semaglutide 2.4 mg compared to placebo in adults with overweight or obesity and type 2 diabetes6.
Safety Profile and Adverse Events
The safety profile of semaglutide is consistent with other GLP-1RAs. The most common adverse events are gastrointestinal, including nausea, vomiting, and diarrhea, which are generally mild to moderate in severity1 2 4 6. There are also concerns about the potential risks of pancreatitis, pancreatic cancer, and thyroid cancer, although definitive conclusions cannot be drawn due to the low incidence of these conditions1. Additionally, semaglutide has been associated with an increased risk of biliary disease, such as cholelithiasis1.
Cardiovascular and Renal Safety
Semaglutide has shown beneficial effects on cardiovascular outcomes. The cardiovascular safety of semaglutide was demonstrated to be noninferior to placebo, with observations suggesting a similar cardiovascular profile to that of subcutaneous semaglutide8. In patients with moderate renal impairment, semaglutide was effective and its safety profile was consistent with the GLP-1RA class, indicating its potential as a treatment option for this population3.
Comparison with Other Diabetes Medications
In head-to-head trials, semaglutide has shown superior efficacy compared to other diabetes medications. For instance, in the PIONEER 7 trial, oral semaglutide with flexible dose adjustments provided superior glycemic control and weight loss compared to sitagliptin5. Similarly, the SUSTAIN 2 trial demonstrated that once-weekly semaglutide was more effective than sitagliptin in reducing HbA1c and body weight in patients inadequately controlled on metformin or thiazolidinediones7.
Conclusion
Semaglutide, as a member of the GLP-1RA drug class, offers significant benefits in glycemic control and weight loss for patients with type 2 diabetes. Its availability in both subcutaneous and oral formulations provides flexibility in administration, potentially improving patient adherence. While gastrointestinal side effects are common, they are typically mild to moderate. The drug's cardiovascular and renal safety profiles further support its use as a valuable treatment option in the management of type 2 diabetes.
Sources and full results
Most relevant research papers on this topic
Safety of Semaglutide
Semaglutide has a favorable risk/benefit profile for type 2 diabetes patients, with mostly mild gastrointestinal disturbances and increased risk of biliary disease, but no unexpected safety issues.
Literature Review
Highly CitedSafety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Oral semaglutide is a safe and well-tolerated GLP-1 analogue suitable for once-daily dosing in healthy and type 2 diabetes patients.
RCTHighly CitedEfficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Oral semaglutide is effective and safe for patients with type 2 diabetes and moderate renal impairment, improving glucose control and bodyweight reduction.
RCT
Large Human TrialHighly CitedSemaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Semaglutide once weekly as an add-on to SGLT-2 inhibitor therapy significantly improves HbA1c levels and bodyweight in patients with inadequately controlled type 2 diabetes.
RCTLarge Human TrialHighly CitedEfficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Oral semaglutide with flexible dose adjustments is more effective and safer than sitagliptin in achieving HbA1c levels below 7% in type 2 diabetes patients.
RCTLarge Human TrialHighly CitedSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Semaglutide 24 mg once a week effectively manages weight in adults with overweight or obesity and type 2 diabetes, with more patients achieving at least 5% weight reduction compared to placebo.
RCTLarge Human Trial
Rigorous JournalHighly CitedEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Once-weekly semaglutide is more effective and safe than once-daily sitagliptin for improving glycemic control in patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both.
RCTLarge Human TrialHighly CitedA Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Oral semaglutide effectively controls type 2 diabetes, reduces body weight, and lowers systolic blood pressure, with a well-tolerated safety profile and potential for earlier diabetes treatment.
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Oral semaglutide monotherapy is effective and safe in reducing HbA1c levels in Japanese patients with type 2 diabetes, with dose-dependent effects compared to placebo and subcutaneous GLP-1 receptor agonist liraglutide 09 mg.
RCTHighly CitedOral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Oral semaglutide is a viable option for treating type 2 diabetes, with potential benefits in preventing cardiovascular events and increasing weight loss.
Systematic Review